Nick Arab, Pattern Bioscience CEO
Pattern Bioscience raises $28.7M Series C for faster, more efficient antibiotic resistance test
The team at Pattern Bioscience is working on a test that can diagnose drug-resistant bacterial infections and identify effective antibiotics within hours, far faster than the days it can take for tests based on cultures, the current standard of care.
They’re starting out with hospitalized patients with pneumonia, and thanks to a $28.7 million Series C financing round, Pattern says it can finish development of the test, conduct validation studies and eventually submit to the FDA for review.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters